Suppr超能文献

老年人的肺炎球菌疾病:是什么阻碍了疫苗的效力?

Pneumococcal disease in the elderly: what is preventing vaccine efficacy?

作者信息

Rubins J B, Janoff E N

机构信息

Pulmonary Diseases, Veterans Affairs Medical Center and Department of Medicine, University of Minnesota School of Medicine, Minneapolis 55417, USA.

出版信息

Drugs Aging. 2001;18(5):305-11. doi: 10.2165/00002512-200118050-00001.

Abstract

The effective prevention of Streptococcus pneumoniae infection has a renewed priority in an era in which the emergence of antibacterial-resistant strains has the potential to further compromise efforts to reduce early mortality from invasive pneumococcal infection. Although the 23-valent pneumococcal polysaccharide (PPS) vaccine was approved in the US to prevent respiratory and invasive infection in the elderly and other high-risk populations, the protective efficacy of this vaccine for the growing population of adults aged >65 years remains controversial. The apparent effectiveness of pneumococcal immunisation in clinical studies of elderly adults has varied depending upon whether a reduction in pneumococcal colonisation, pneumonia, bacteraemia or death was used as an outcome. Clinical studies of vaccine efficacy to date suggest that the current pneumococcal vaccine is 56 to 81% effective at preventing invasive pneumococcal infection, and may have additive benefit to influenza vaccine in preventing community-acquired pneumonia, particularly in elderly adults with an increased risk of serious pneumonia requiring hospitalisation. Possible reasons for incomplete protection from pneumococcal infection after immunisation include infection with non-vaccine serotypes, inadequate or ineffective antibody responses, waning of antibody responses, or compromised nonhumoral host defences. Further studies are needed to determine whether: (i) elderly adults who respond poorly to the 23-valent pneumococcal vaccine can be identified prior to immunisation and targeted for study with improved pneumococcal vaccines; (ii) specific nutrient deficiencies can be identified and corrected to improve the immune responsiveness of elderly adults to the PPS vaccine; (iii) newer protein-conjugate or DNA pneumococcal vaccines may be more uniformly immunogenic for elderly adults; and (iv) whether smoking cessation reduces the risk of invasive pneumococcal infection in elderly adults.

摘要

在抗菌耐药菌株的出现有可能进一步危及降低侵袭性肺炎球菌感染早期死亡率努力的时代,有效预防肺炎链球菌感染再次成为当务之急。尽管23价肺炎球菌多糖(PPS)疫苗在美国已获批准用于预防老年人及其他高危人群的呼吸道和侵袭性感染,但该疫苗对日益增多的65岁以上成年人的保护效力仍存在争议。在老年成年人的临床研究中,肺炎球菌免疫接种的明显效果因所采用的结果是肺炎球菌定植、肺炎、菌血症还是死亡的减少而有所不同。迄今为止的疫苗效力临床研究表明,目前的肺炎球菌疫苗在预防侵袭性肺炎球菌感染方面有56%至81%的效力,并且在预防社区获得性肺炎方面可能对流感疫苗有附加益处,尤其是在有严重肺炎需要住院风险增加的老年成年人中。免疫接种后对肺炎球菌感染保护不完全的可能原因包括感染非疫苗血清型、抗体反应不足或无效、抗体反应减弱或非体液宿主防御受损。需要进一步研究以确定:(i)在免疫接种前能否识别出对23价肺炎球菌疫苗反应不佳的老年成年人,并针对改进的肺炎球菌疫苗进行研究;(ii)能否识别并纠正特定的营养缺乏以提高老年成年人对PPS疫苗的免疫反应性;(iii)更新的蛋白结合或DNA肺炎球菌疫苗对老年成年人是否可能具有更一致的免疫原性;以及(iv)戒烟是否能降低老年成年人侵袭性肺炎球菌感染的风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验